Group 1 - Company shares of 华检医疗 (01931) have increased over 15%, with a cumulative rise of more than 120% in the month [1] - As of the report, the stock price is at 4.91 HKD, with a trading volume of 13.82 million HKD [1] - The company announced a strategic cooperation framework agreement with 华大共赢 to establish the IVD-BGI CoWin innovation drug intellectual property tokenization fund [1] Group 2 - The fund will invest in projects under the NewCo + RWA Web3 exchange ecosystem in Hong Kong, the US, or other overseas regions [1] - 华大共赢, initiated by the biotechnology leader 华大基因, has extensive investment experience and project resources in the innovative medical and pharmaceutical fields [1] - The company aims to address the pharmaceutical industry's pain points, where new drug development takes 10 years and 80% of funding is spent in clinical stages, by allowing ordinary investors access to high-value medical assets through RWA technology [1] Group 3 - The solution involves converting high-value medical assets, such as phase II clinical ADC drugs and gene therapy patents, into tradable digital certificates [1] - The goal is to become the "Nasdaq + Uniswap" in the medical RWA field, ensuring compliance while achieving decentralized liquidity [1]

智通财经APP在《稳定币条例生效前夜华检医疗(01931)收获三张实际"信任票"》中指出，公司构建名 为"IVDNewCo Exchange"的Web3交易所生态，直击医药行业痛点：一款新药研发需10年，80%资金砸 在临床阶段，普通投资者却被拒之门外。华检医疗的解决方案是将高价值医疗资产——如Ⅱ期临床的 ADC药物、基因疗法专利——通过RWA技术转化为可分割交易的数字凭证。其目标明确：成为医疗 RWA领域的"纳斯达克+Uniswap"，既保障合规性，又实现去中心化流动性。 华检医疗(01931)再涨超15%，月内累计涨幅已超120%。截至发稿，涨13.92%，报4.91港元，成交额 1382万港元。 消息面上，华检医疗(01931)发布公告，与华大共赢订立战略合作框架协议，共同建立华检华大共赢创 新药知识产权代币化基金(IVD-BGI CoWin)，该基金将于中国香港/美国或其他海外地区投资于公司 NewCo+RWA Web3交易所生态运作模式下的项目。作为由生物技术领导者华大基因（300676）发起的 企业风险投资(CVC)实体，华大共赢拥有多年于创新医疗（002173）及创新药领域的国内外投资经验及 项 ...